Related Experiment Video
Updated: Jun 28, 2026
Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow
Published on: November 4, 2016
[Effect of PD-L1 blockade on function of dendritic cells derived from chronic myelocytic leukemia]
Chun-Yan Wang1, Lian-Sheng Zhang, Fa-Qing Tian
1Department of Hematology and Oncology, The Second Hospital, Lanzhou University, Lanzhou, 730030, Gansu Province, China.
Insights
Blocking Programmed death-1 ligand-1 (PD-L1) on dendritic cells (DCs) from chronic myelocytic leukemia (CML) patients enhances their immune function. This approach boosts anti-tumor immunity, offering new possibilities for DC-based vaccination strategies.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Programmed death-1 ligand-1 (PD-L1) is a B7 family molecule that inhibits immune responses.
- Dendritic cells (DCs) derived from chronic myelocytic leukemia (CML) patients exhibit impaired immunological function.
Purpose of the Study:
- To enhance the immunological function of CML-derived DCs by blocking PD-L1 expression.
- To investigate the potential of PD-L1 blockade in improving DC-based anti-tumor immunity.
Main Methods:
- CML patient bone marrow mononuclear cells (BMMNCs) were differentiated into DCs using a cytokine cocktail (rhGM-CSF, rhIL-4, TNF-alpha).
- DC phenotypes were analyzed via flow cytometry.
- Mixed lymphocyte reactions were assessed using MTT assays.
- Interferon-gamma (IFN-gamma), IL-2, and IL-10 levels in cell culture supernatants were quantified by ELISA.
Main Results:
- PD-L1 expression was upregulated on mature CML-derived DCs.
- PD-L1 blockade enhanced T lymphocyte proliferation.
- Blockaded DCs increased secretion of IL-2 and IFN-gamma.
- PD-L1 blockade inhibited IL-10 production.
Conclusions:
- PD-L1 blockade significantly enhances the immunostimulatory capability of CML-derived DCs.
- This strategy presents a promising avenue for developing effective DC-based anti-tumor vaccination.
- Targeting PD-L1 on CML-DCs can overcome immune suppression and promote anti-leukemic responses.
Abstract:
Programmed death-1 ligand-1(PD-L1) is a recently identified member of the B7 family molecules and is shown to mediate the inhibition of immune responses. This study was purposed to enhance the weak immunological function of dendritic cells (DCs) derived from the patients with chronic myelocytic leukemia (CML) by blockade of the expression of PD-L1. Bone marrow mononuclear cells (BMMNCs) of CML patients were induced into DCs in the presence of cytokine cocktail of rhGM-CSF, rhIL-4 and TNF-alpha. The phenotypes of DCs were detected by flow cytometry, mixed lymphocyte reaction was analyzed by MTT assay and IFN-gamma, IL-2 and IL-10 in the cell culture supernatant were detected by ELISA. The results showed that the expression of PD-L1 on CML-DCs was upregulated with the maturation of CML-DCs. PD-L1-blockaded DCs could enhance T lymphocyte proliferation, increase the secretion of IL-2 and IFN-gamma, and inhibit the production of IL-10. Taken together, PD-L1-blockaded DCs originated from CML cells had more potent immunostimulatory capability. It is concluded that PD-L1 blockaded can enhance the function of CML-DCs. This approach presents new possibilities for achieving anti-tumor immunity by DC-based vaccination.
More Related Videos
10:18Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
11:48Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
Published on: May 31, 2018